Moreover, our experiments suggested that triple therapy with gefitinib, crizotinib and bevacizumab exerted the most significant inhibitory effect on downstream signaling and cell proliferation in EGFR-mutant NSCLC cells with concomitant aberrant MET activation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.